Body Mass Index and Survival after Cancer Diagnosis: A Pan-Cancer Cohort Study of 114 430 Patients with Cancer

Huakang Tu,Jennifer L. McQuade,Michael A. Davies,Maosheng Huang,Kunlin Xie,Yuanqing Ye,Wong-Ho Chow,Alma Rodriguez,Xifeng Wu
DOI: https://doi.org/10.1016/j.xinn.2022.100344
2022-01-01
Abstract:The recommendation encouraging patients with cancer to keep a normal body mass index (BMI) is largely extrapolated from data on risk of developing cancer. We tested the prospective association between peri-diagnostic (within 1 year post-diagnosis) BMI and all-cause mortality in patients with incident cancers. During 7.2 years of follow-up, 42% (48,340) of the 114 430 patients with cancer died. Spline analysis revealed that compared with a BMI of 22.5, a BMI lower than 22.5 was associated with increased risk of all-cause mortality across 24 cancer types. A BMI higher than 22.5 was associated with reduced all-cause mortality, while a non-linear association was observed; the lowest risk was found at a BMI of 29.6-34.2, and the risk started to return to and above unity at very high BMI values. The reduced mortality risk of high BMI was observed in 23 of 24 cancer types and maintained after attempts to remove potential selection bias, confounding by smoking and comorbidities, and reserve causality. Compared with a normal BMI of 18.5-24.9, the hazard ratios were 0.85 (95% confidence interval [CI], 0.830.87) for an overweight BMI (25-29.9) and 0.82 (0.80-0.85) for an obese BMI (>= 30), and the associations were generally consistent across cancer types and various subgroups. Obese BMI was associated with increased life expectancy, up to 6 years among men and 3 years among women. In conclusion, while overweight/obese BMI increases the risk of developing cancer in the general population, overweight/obese peri-diagnostic BMI was associated with longer survival in cancer patients.
What problem does this paper attempt to address?